• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Nov 1, 2013; 123(11): 4681–4694.
Published online Oct 8, 2013. doi:  10.1172/JCI65764
PMCID: PMC3809775

Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression

Abstract

RAS is the most frequently mutated oncogene in human cancers. Despite decades of effort, anti-RAS therapies have remained elusive. Isoprenylcysteine carboxylmethyltransferase (ICMT) methylates RAS and other CaaX-containing proteins, but its potential as a target for cancer therapy has not been fully evaluated. We crossed a Pdx1-Cre;LSL-KrasG12D mouse, which is a model of pancreatic ductal adenocarcinoma (PDA), with a mouse harboring a floxed allele of Icmt. Surprisingly, we found that ICMT deficiency dramatically accelerated the development and progression of neoplasia. ICMT-deficient pancreatic ductal epithelial cells had a slight growth advantage and were resistant to premature senescence by a mechanism that involved suppression of cyclin-dependent kinase inhibitor 2A (p16INK4A) expression. ICMT deficiency precisely phenocopied Notch1 deficiency in the Pdx1-Cre;LSL-KrasG12D model by exacerbating pancreatic intraepithelial neoplasias, promoting facial papillomas, and derepressing Wnt signaling. Silencing ICMT in human osteosarcoma cells decreased Notch1 signaling in response to stimulation with cell-surface ligands. Additionally, targeted silencing of Ste14, the Drosophila homolog of Icmt, resulted in defects in wing development, consistent with Notch loss of function. Our data suggest that ICMT behaves like a tumor suppressor in PDA because it is required for Notch1 signaling.

Introduction

RAS is the most frequently mutated oncogene in human cancer (1).

This has made RAS the target of drug discovery efforts for more than three decades, but effective anti-RAS therapies have remained elusive (2). RAS is a prototypical small GTPase that functions as a binary molecular switch to regulate a number of signaling pathways including those that control growth and differentiation. RAS is inactive when GDP bound and is active when it binds GTP. The GDP/GTP cycle is controlled by guanine nucleotide exchange factors (GEFs) that activate RAS and by GTPase-activating proteins (GAPs) that dramatically accelerate the rate of GTP hydrolysis catalyzed by RAS, thereby limiting RAS activity (3). The oncogenic mutations found in human cancer are one of several single nucleotide changes in codons 12, 13, or 61 that render RAS insensitive to GAPs and reduce the intrinsic rate of GTP hydrolysis, thus allowing the accumulation of GTP-bound, activated RAS (1, 4). Attempts to devise therapeutic agents that reverse the accumulation of GTP-bound RAS have failed. Accordingly, investigators have taken an alternate approach driven by another hallmark of RAS biology: its regulation of signaling pathways only when associated with cellular membranes (5).

RAS is a peripheral membrane protein that gains affinity for membranes as a consequence of a series of posttranslational modifications of a C-terminal CaaX motif (6). The CaaX sequence is first modified by farnesyltransferase (FTase), which adds a farnesyl lipid to the cysteine. Next, RAS-converting enzyme 1 (RCE1) removes the aaX amino acids. Finally, isoprenylcysteine carboxylmethyltransferase (ICMT) methyl esterifies the α-carboxyl group of the newly formed C-terminal farnesylcysteine. The end result of the three modifications is to render the C terminus of RAS hydrophobic with affinity for phospholipid bilayers (6). The three CaaX-modifying enzymes have long been considered targets for anti-RAS drug discovery because inhibiting one or more of the steps of this pathway should render RAS more cytosolic and thereby reduce signaling to downstream effectors. Indeed, FTase inhibitors (FTIs) were developed two decades ago (7). However, despite their favorable attributes as drugs and their success in blocking FTase activity in vivo, they proved ineffective as anticancer drugs because oncogenic RAS could remain active by modification with another prenyltransferase (8). This result focused attention on RCE1 and ICMT as alternative drug targets.

To validate ICMT as a target for anticancer drug discovery, we engineered mice with a conditional allele for the Icmt gene Icmtflx, in which exon 1 of Icmt is flanked by LoxP sites (9). Of the three RAS isoforms expressed in mammalian tissues, KRAS was selected for analysis because the vast majority of human cancers driven by oncogenic RAS are associated with mutations of the KRAS gene (1). When mouse embryonic fibroblasts (MEFs) from Icmtflx/flx animals were transfected with oncogenic KrasG12V, they became transformed. Importantly, when Icmt was ablated in the transformed cells by infection with an adenovirus directing the expression of Cre recombinase, the transformed phenotype was reverted and could be restored by reexpression of ICMT (9). This result was concordant with the effects of Icmt ablation on two in vivo models of KRAS-driven neoplasia, both of which used a latent, Cre-inducible oncogenic LSL-KrasG12D allele (10). ICMT deficiency ameliorated the myeloproliferative disease observed in Mx1-Cre;LSL-KrasG12D mice and prolonged survival in LSL-KrasG12D mice bred with animals containing a lysozyme M-Cre allele that expresses Cre in type 2 pneumocytes and therefore produces lung tumors (10).

These studies support the idea that ICMT is a good target for anti-KRAS drug discovery. However, neither the myeloproliferative disease observed in Mx1-Cre;LSL-KrasG12D mice, nor the lung tumors seen in M-Cre;LSL-KrasG12D animals are genetically or histologically faithful to the analogous diseases seen in humans. In contrast, the neoplastic transformation and disease progression observed in the pancreas of Pdx1-Cre;LSL-KrasG12D mice faithfully mimics the progression of human pancreatic ductal adenocarcinoma (PDA) through a series of precursor lesions known as pancreatic intraepithelial neoplasias (PanINs) (11, 12). Moreover, not only is PDA among the human cancers most frequently associated with oncogenic mutations in the KRAS gene (13), but activating mutations in the KRAS proto-oncogene have been found in patients with early PanIN lesions (14), suggesting that KRAS mutations may be an initiating genetic event for PDA. We therefore sought to further investigate the role of ICMT in KRAS-driven cancer using the Pdx1-Cre;LSL-KrasG12D model of PDA. To accomplish this, we compared Icmtflx/+;Pdx1-Cre;LSL-KrasG12D with Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice, expecting to see an amelioration of disease in the setting of ICMT deficiency. We were instead surprised to observe a marked acceleration of PanIN progression to PDA in ICMT-deficient pancreata. Despite partial subcellular mislocalization in pancreatic tissue, oncogenic KRAS signaling was preserved in the setting of ICMT deficiency. Notch1 is a known tumor suppressor in the Pdx1-Cre;LSL-KrasG12D model of PDA (15, 16), and we found that ICMT deficiency phenocopied Notch1 deficiency and that efficient Notch signaling in both human tumor cells and Drosophila required ICMT. Thus, in the Pdx1-Cre;LSL-KrasG12D model of pancreatic neoplasia, ICMT behaves like a tumor suppressor because it is required for Notch1 signaling.

Results

ICMT is not required for normal pancreatic development.

In addition to the four isoforms of RAS, ICMT has as many as 300 potential substrates including a broad range of signaling molecules that regulate, among other processes, cell growth, the actin cytoskeleton, vesicular transport, and nuclear architecture (1719). We therefore sought to determine whether pancreata can develop normally in mice genetically engineered to lose ICMT expression in the pancreas. To answer this question, we used mice transgenic for a Pdx1-Cre allele that drives expression of Cre recombinase under the control of the Pdx1 promoter (11). In these animals, Cre recombinase is expressed, beginning at E8.5, in pancreatic progenitor cells that give rise to adult acinar, ductal, and islet cells. We crossed the Pdx1-Cre mice with Icmtflx/flx mice that are homozygous for an allele of Icmt in which the first exon is flanked by LoxP sites (floxed) (9). Cre-mediated deletion of the first exon of Icmt in mouse fibroblasts has been shown to result in a complete loss of the enzymatic activity and in an accumulation of unmethylated ICMT protein substrates (9). We bred mice with the genotypes Icmtflx/+;Pdx1-Cre and Icmtflx/flx;Pdx1-Cre, in which either one or both Icmt genes are inactivated in the pancreas. Mice of both genotypes were born at the expected Mendelian ratios and gained weight normally. No evidence of pancreatic insufficiency or diabetes was observed (Supplemental Figure 1A). A cohort of mice (n = 4) was followed for 1 year and remained healthy. These mice were sacrificed and subjected to necropsy. The ICMT-deficient pancreata of the 1-year-old mice appeared histologically normal (Supplemental Figure 1B).

The Pdx1-Cre transgene has been reported to be expressed in a mosaic pattern in the pancreas (11, 20). We were therefore concerned that the normal pancreata in Icmtflx/flx;Pdx1-Cre mice might result from progenitor cells that escaped ablation of Icmt. In order to determine whether Cre recombinase is expressed efficiently in Pdx1-Cre transgenic pancreata, regardless of Icmt status, we crossed Icmtflx/+;Pdx1-Cre and Icmtflx/flx;Pdx1-Cre mice with Rosa26-LSL-LacZ (R26R) reporter mice (21) and analyzed sections of pancreata for β-gal expression using X-gal staining. Whereas pancreatic tissue stained blue, extrapancreatic structures such as blood vessels and lymph nodes were negative for β-gal (Supplemental Figure 1C). We observed uniform expression of β-gal in the pancreata of Icmtflx/+;Pdx1-Cre;Rosa26-LSL-LacZ mice (Supplemental Figure 1C), indicating that Pdx1-Cre expression occurred throughout the pancreas and that heterozygosity at the Icmt locus did not affect pancreatic development. In contrast, whereas the majority of acinar, ductal, and islet cells in the pancreata of Icmtflx/flx;Pdx1-Cre;Rosa26-LSL-LacZ animals stained positively for β-gal, a minor population of pancreatic cells did not, confirming a mosaic expression of Cre and suggesting a subtle growth disadvantage for ICMT-deficient cells (Supplemental Figure 1C). Importantly, despite the mosaicism, in all animals examined, there was a substantial contribution of Cre-expressing (β-gal–positive) cells to all major pancreatic structures including ducts, acini, and islets, indicating that ICMT-deficient cells were able to contribute to normal pancreatic development.

To confirm that recombination of the Icmtflx allele resulted in loss of enzymatic activity, we removed portions of pancreata from 2-month-old mice of the genotypes Icmtflx/flx;Pdx1-Cre and Icmtflx/+;Pdx1-Cre, homogenized the tissue, isolated crude membrane fractions, and assayed the membranes for ICMT activity (22). Whereas robust activity was detected in the membrane preparations from Icmtflx/+;Pdx1-Cre mice, membranes from Icmtflx/flx;Pdx1-Cre mice possessed very low activity (Supplemental Figure 1D). These results demonstrate that ICMT can be ablated in the embryonic pancreas without developmental consequences.

ICMT deficiency exacerbates PanIN development in a mouse model of PDA.

To determine the role of ICMT in KRAS-driven PDA, we chose a mouse model that faithfully recapitulates the progression of human disease by inducing PanINs (11). LSL-KrasG12D mice have a Kras gene with a G12D-activating mutation knocked into the Kras locus. Importantly, the oncogene is preceded by a stop transcription (S) site flanked by LoxP (L) sites to yield a so-called Lox-STOP-Lox (LSL) allele. In the presence of Cre recombinase, the STOP element is excised, allowing expression of the oncogene from its endogenous promoter. When Cre recombinase is introduced in a pancreas-specific fashion by crossing with Pdx1-Cre transgenic animals, 100% of the mice develop PanIN lesions that gradually progress, such that a significant proportion of mice develop PDA, although malignancy appears late at approximately 12 months of age.

In order to test whether ICMT deficiency would delay or inhibit the progression of PanINs, we crossed the Pdx1-Cre;LSL-KrasG12D mice with mice carrying the floxed allele of Icmt (Icmtflx/flx). We generated mice with the experimental genotype Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D and littermate control animals with the genotype Icmtflx/+;Pdx1-Cre;LSL-KrasG12D, which retained a wild-type copy of Icmt, even in the presence of Cre. Mice of both genotypes were born at the expected Mendelian ratios and gained weight normally. Animals of both genotypes were sacrificed at intervals following birth and subjected to necropsy. PCR of genomic DNA from the pancreas, liver, and spleen confirmed recombination of the floxed alleles Icmtflx/+, Icmtflx/flx, and LSL-KrasG12D in the pancreas but not in other tissues (not shown).

The pancreata of Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice appeared grossly abnormal (Figure (Figure1A).1A). They were larger and more fibrotic than pancreata from age-matched controls (1.24 ± 0.15 g vs. 0.79 ± 0.12 g at 8 months; n = 13; P < 0.01) and frequently showed cysts (Figure (Figure1A).1A). Strikingly, the pancreata of 2- to 3-month-old mice of the experimental genotype were found to contain vastly more PanIN lesions than control animals (Figure (Figure1,1, A and C, and Supplemental Figure 3A). Indeed, by 6 months of age, almost all of the normal pancreatic architecture was replaced by abnormal ducts and PanINs in Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice, whereas, despite numerous PanINs, areas of normal ducts and acini were readily apparent in Icmtflx/+;Pdx1-Cre;LSL-KrasG12D mice (Figure (Figure1B).1B). Analysis of the histological grade of PanINs (23) revealed that the lesions progressed more rapidly to more advanced stages in Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D animals than in Icmtflx/+;Pdx1-Cre;LSL-KrasG12D animals (Figure (Figure1C).1C). Thus, in addition to increasing the number of PanINs, ICMT deficiency accelerated the progression to more advanced stages of disease.

Figure 1
ICMT deficiency exacerbates PanIN lesions in Pdx1-Cre;LSL-KrasG12D mice.

ICMT deficiency alone is insufficient to induce pancreatic neoplasia.

We observed no evidence of PanIN development or other neoplastic change in the pancreata of ICMT-deficient animals that did not express KRASG12D (Supplemental Figure 1B), indicating that the effects of ICMT deficiency depend on oncogenic Kras. Inactivation of the tumor suppressor p53, for example, with a dominant-negative p53R172H allele, dramatically accelerates many oncogene-driven cancers, including KRASG12D-driven PDA in mice (24). Like Icmtflx/flx;Pdx1-Cre mice, Icmtflx/flx;Pdx1-Cre;LSL-p53R172H animals failed to develop any pancreatic neoplasm (Supplemental Figure 2). Thus, ICMT deficiency was incapable of inducing pancreatic neoplasia in the absence of oncogenic KRAS, even when p53 was inactivated.

ICMT deficiency increases the incidence of KRASG12D-induced acinar-ductal metaplasia in the pancreas.

The virtual replacement of normal pancreatic architecture with PanINs observed in 6-month-old Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice suggested a dramatic proliferation of ductal epithelial cells combined with a loss of acinar cells, which may occur by a process known as acinar-ductal metaplasia (ADM). ADM has been associated with PanIN lesions in human pancreatic samples as well as in the early changes seen in KRASG12D-driven models of PDA (25). To detect ADM, we stained frozen sections of the pancreata from control and experimental 2-month-old animals using antibodies against the acinar cell marker amylase and the ductal cell marker cytokeratin-19 (CK19) (Figure (Figure2A).2A). In the pancreata from Icmtflx/+;Pdx1-Cre;LSL-KrasG12D control mice, the cells staining positive for CK19 were negative for amylase and vice versa. This is likely because ADM is a transitory stage occurring at a low frequency in these pancreata and therefore was not captured in the sections examined. In contrast, PanIN lesions in the pancreata of Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice revealed clusters of cells that stained for both markers, indicating higher levels of ADM (Figure (Figure2,2, A and B). H&E staining of these pancreata revealed areas where ducts appeared to be developing from acinar tissue, consistent with ADM (Figure (Figure22C).

Figure 2
Acinar-to-ductal metaplasia contributes to PanINs in ICMT-deficient pancreata.

ICMT deficiency worsens the fibrosis and inflammation associated with KrasG12D-induced PanIN development.

Abundant desmoplastic stroma is one of the hallmarks of PDA (26). The desmoplastic stroma consists of ECM, activated fibroblasts, inflammatory cells, and neovasculature. Desmoplastic stroma is seen in human tumors and is associated with PanINs in pancreata from Pdx1-Cre;LSL-KrasG12D mice (11). We observed that the pancreata of Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice were larger and more fibrotic than age-matched Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D animals. Consistent with this observation, sections of pancreata from 2-month-old mice stained with Masson’s trichrome revealed deposition of collagen (Figure (Figure3,3, A and B), which is the hallmark of fibrosis (27), and were positive for α-smooth muscle actin, a marker of activated pancreatic stellate cells (Supplemental Figure 3B). Strikingly, while pancreata from Icmtflx/+;Pdx1-Cre;LSL-KrasG12D mice stained positive for collagen and activated pancreatic stellate cells in the immediate vicinity of the PanIN lesions, pancreata from Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice revealed a much higher degree of fibrosis with substantial areas of collagen stretching throughout the organ (Figure (Figure3,3, A and B, and Supplemental Figure 3B). To determine whether the enhanced deposition of collagen was also associated with an increased inflammatory infiltrate, we stained frozen sections of pancreata from the same animals with antibodies directed against the panleukocytic marker CD45. The ICMT-deficient pancreata showed markedly increased staining for CD45 compared with the KRASG12D-expressing pancreata that also expressed ICMT, indicating an enhanced inflammatory response in ICMT-deficient pancreata (Figure (Figure3,3, C and D).

Figure 3
Accelerated fibrosis and leukocytic infiltration associated with PanINs in mice expressing oncogenic KRAS in the setting of ICMT deficiency.

ICMT deficiency leads to partial mislocalization of KRAS in pancreatic cells but does not affect KRAS-driven MAPK signaling or epithelial proliferation.

We have previously shown that GFP-RAS fusion proteins are partially mislocalized from the plasma membrane to the cytosol and internal membranes in ICMT-deficient MEFs (28, 29). In order to confirm the mislocalization of KRAS in ICMT-deficient pancreata, we examined the distribution of endogenous KRAS in subcellular fractionations. Pancreata from 3-month-old Icmtflx/+;Pdx1-Cre or Icmtflx/flx;Pdx1-Cre mice were homogenized and fractionated. KRAS was found almost exclusively in the P100 membrane fraction of pancreata from Icmtflx/+;Pdx1-Cre mice, consistent with previous reports (29). In contrast, KRAS was evenly distributed between the P100 and S100 fractions from the homogenates of Icmtflx/flx;Pdx1-Cre pancreata (Figure (Figure4A).4A). Indeed, the relative content of KRAS in the cytosol (S100) increased 7-fold in ICMT-deficient pancreata relative to control.

Figure 4
ICMT deficiency mislocalizes KRAS in pancreatic cells but does not inhibit ERK activation or proliferation.

The observation that oncogenic KRAS does not require methylation by ICMT to induce PanINs suggests that KRAS signaling is intact in ICMT-deficient pancreatic cells, despite partial mislocalization to the cytosol. To confirm this conclusion, we studied ERK activation in PanIN lesions. Upregulation of nuclear phospho-ERK (pERK) staining downstream of KRASG12D expression is an early feature of mouse PanIN lesions, whereas normal pancreatic tissue is negative for pERK staining (30, 31). We observed similar levels of staining for pERK by immunohistochemistry in early PanIN lesions in pancreata from both Icmtflx/+;Pdx1-Cre;LSL-KrasG12D and Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice (Figure (Figure4B).4B). This suggests that KRASG12D stimulates the MAPK pathway in the pancreas even in the absence of ICMT and is consistent with the observation that, while silencing ICMT in HeLa cells slightly diminishes GTP-loading of RAS and inhibits pERK by 25%, it does not eliminate RAS/MAPK signaling (Supplemental Figure 4). Concordant with the observation that KRAS-stimulated MAPK signaling was preserved in ICMT-deficient pancreata, the PanIN lesions in the pancreata of both Icmtflx/+;Pdx1-Cre;LSL-KrasG12D and Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice stained for Ki67 to similar degrees (Figure (Figure4C),4C), indicating similar levels of proliferation in both genotypes.

ICMT deficiency does not significantly affect the survival of mice expressing oncogenic KrasG12D and dominant-negative p53R172H in the pancreas.

The progression of PanINs to invasive, metastatic PDA in the LSL-KrasG12D;Pdx1-Cre mouse model occurs at low penetrance and with a latency of close to 1 year (11). In order to determine whether the acceleration of PanIN progression in Icmtflx/flx;LSL-KrasG12D;Pdx1-Cre mice was associated with increased PDA, we examined pancreata from Icmtflx/+;LSL-KrasG12D;Pdx1-Cre and Icmtflx/flx;LSL-KrasG12D;Pdx1-Cre mice sacrificed at various ages. The Icmtflx/flx;LSL-KrasG12D;Pdx1-Cre mice showed an increased percentage of areas of PDA compared with controls at each age, with the earliest observed case occurring at 5.7 months of age versus 7.7 months in the control animals (Figure (Figure5A).5A). Two mice from each genotype were found to have metastases in the liver at the time of necropsy (Figure (Figure55B).

Figure 5
ICMT deficiency accelerates the development of PDA but does not significantly affect the survival of mice expressing oncogenic KRASG12D and dominant-negative p53R172H in the pancreas.

The long latency of PDA in both genotypes made survival studies challenging. We therefore sought to accelerate the progression to PDA by inactivating a relevant tumor suppressor. p53R172H has been shown to accelerate the progression to PDA in the LSL-KrasG12D;Pdx1-Cre model and to decrease survival to 5 months (24). We therefore bred an LSL-p53R172H allele into our mice, generating Icmtflx/flx;LSL-KrasG12D;Pdx1-Cre;LSL-p53R172H and Icmtflx/+;LSL-KrasG12D;Pdx1-Cre;LSL-p53R172H animals, which were followed until they succumbed or showed signs of significant illness. ICMT deficiency decreased survival, but the magnitude of the effect was small and did not reach statistical significance (Figure (Figure5C).5C). At necropsy, mice from both genotypes were found to harbor large primary tumors in the pancreas, with frequent metastatic lesions in the liver (Figure (Figure55D).

ICMT deficiency in the pancreas does not increase susceptibility to cerulein-induced inflammation.

The exacerbation of PanIN lesions in Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice in the setting of unaffected RAS/MAPK signaling suggests that ICMT deficiency may affect disease progression through a non–cell-autonomous mechanism. Chronic pancreatitis is a significant risk factor for PDA in humans (32). Because the accelerated PanINs observed in ICMT-deficient pancreata were associated with an inflammatory infiltrate (Figure (Figure3,3, C and D), we tested the hypothesis that the accelerated KRASG12D-induced PanIN development seen in mice lacking ICMT in the pancreas was due either to an increased susceptibility to inflammation or to a failure to efficiently resolve an inflammatory insult. To test this hypothesis, we used cerulein-induced pancreatitis because it is the best-studied mouse model of inflammation in this organ. Cerulein is an analog of cholecystokinin that, when administered to rodents in supraphysiologic doses, stimulates premature intracellular activation of pancreatic digestive enzymes that cause tissue damage resulting in pancreatitis (33, 34). Icmtflx/flx;Pdx1-Cre and Icmtflx/+;Pdx1-Cre mice were treated with 7 hourly i.p. injections of cerulein over a period of 2 days to induce acute pancreatitis (35). No difference was observed in the degree of inflammation observed in the two genotypes (Supplemental Figure 5A). By day 7 after cerulein administration, the pancreata showed almost complete resolution of inflammation. Again, there was no difference observed with or without pancreatic ICMT (Supplemental Figure 5A). Similar results were obtained when a model of chronic pancreatitis was employed in which mice were treated with 7 hourly cerulein injections, thrice weekly, for 3 weeks (Supplemental Figure 5B). Thus, ICMT deficiency in the pancreas affects neither cerulein-induced pancreatitis nor the resolution of the inflammatory condition.

ICMT-deficient pancreatic ductal cells proliferate more rapidly and are resistant to senescence.

We next sought evidence for a cell-autonomous effect of ICMT deficiency. In order to determine whether pancreatic ductal epithelial cells (PDECs) might have a growth advantage when ICMT deficient, we isolated PDECs from the main pancreatic duct from 2-month-old mice of the genotypes Icmtflx/flx;LSL-KrasG12D, Icmtflx/+;LSL-KrasG12D, Icmtflx/flx, and Icmtflx/+ and cultured them in vitro, embedded in 3DMatrigel culture, where they were grown as spheroids (ref. 36 and Figure Figure6A).6A). To induce recombination of the LoxP sites, the ductal cells were infected with adenovirus-directing expression of Cre recombinase (Adeno-Cre). The efficiency of recombination was confirmed by PCR analysis of genomic DNA isolated from the infected ductal cells (Figure (Figure6B).6B). The PDECs harvested from the Matrigel were replated on conventional tissue culture plastic (2D culture) for 13 days, and the rates of proliferation were measured with an MTS assay. Interestingly, in the absence of oncogenic KRAS, ICMT-deficient PDECs grew faster (Figure (Figure6C).6C). As expected, the growth rate of KRASG12D-transformed PDECs was markedly increased relative to that of untransformed cells expressing ICMT, and ICMT deficiency slightly increased the proliferative rate of KRASG12D-transformed PDECs (Figure (Figure6D).6D). Thus, contrary to expectations, ICMT deficiency increased the growth rate of PDECs independently of RAS transformation.

Figure 6
Cell-autonomous effects: ICMT-deficient PDECs are resistant to premature senescence in 2D culture.

When shifted from 3D to 2D culture, wild-type PDECs undergo premature senescence after approximately 7 days, whereas PDECs expressing KRASG12D do not (37). Senescence is associated with increased expression of the cell cycle inhibitor p16INK4A. PDECs were harvested after 1 and 8 days in 2D culture for analysis of relevant proteins by Western blotting. Parallel samples of cells were fixed after 12 days in 2D culture and stained for expression of senescence-associated β-gal (SAβgal). We observed that, while PDECs from Icmtflx/+ mice infected with Adeno-Cre expressed high levels of p16INK4A 8 days after shifting from 3D to 2D culture, PDECs from Icmtflx/flx mice did not (Figure (Figure6E).6E). Moreover, on day 12, while PDECs from Icmtflx/+ mice showed strong SAβgal expression (Figure (Figure6F)6F) indicating senescence and consistent with the lack of proliferation after 7 days (Figure (Figure6C),6C), PDECs from Icmtflx/flx mice showed markedly reduced SAβgal expression (Figure (Figure6F),6F), concordant with low p16INK4A expression. Thus, ICMT deficiency accelerates the growth of PDECs in tissue culture and allows them to escape premature senescence.

ICMT deficiency phenocopies Notch1 deficiency.

Exacerbation of pancreatic neoplasia without evidence of altered RAS/MAPK signaling suggested that ICMT deficiency may accelerate the disease by affecting another signaling pathway that is independent of RAS, a possibility that is all the more plausible considering that RAS is but one of many substrates for ICMT. One clue to the involvement of another pathway came from a prominent extrapancreatic tumor observed in Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice. Pdx1-Cre has been shown to be leaky in that it is expressed in the epidermis as well as in the pancreas (16). This observation likely explains the cutaneous papillomas that were reported with low penetrance by Hingorani et al. in the initial description of the Pdx1-Cre;LSL-KrasG12D model (11). We observed a dramatic increase in the frequency of papillomas on the faces of Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice (Figure (Figure7A).7A). Fifty-nine percent of animals with this genotype developed these lesions compared with 7% of Icmtflx/+;Pdx1-Cre;LSL-KrasG12D mice. No lesions were observed on Icmtflx/flx;Pdx1-Cre mice, demonstrating that activated KRAS is necessary for these skin tumors. Histologically, the lesions were consistent with verruca vulgaris (Figure (Figure7B).7B). We confirmed Pdx1-Cre expression in these lesions by crossing Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice with animals that harbor a Rosa26-LSL-LacZ allele (Figure (Figure7C).7C). Histopathological examination of some larger lesions revealed areas with an invasive growth pattern with cellular atypia, increased mitosis, and a high degree of keratinization with characteristic keratin “pearls” that are diagnostic of well-differentiated squamous cell carcinoma (Figure (Figure7,7, D–F).

Figure 7
Epidermal tumors in Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice.

Notch1 has been shown to act as a tumor suppressor both in mouse skin (38, 39) and in the pancreas of Pdx1-Cre;LSL-KrasG12D mice (15). Indeed, the exacerbation of PanINs observed in Notch1flx/flx;Pdx1-Cre;LSL-KrasG12D mice (15) was identical to that observed in Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice. Importantly, in addition to accelerated PanINs, Notch1flx/flx;Pdx1-Cre;LSL-KrasG12D mice developed papillomas on the face and neck, particularly below the pinna, that were significantly larger and more frequent than those seen in Pdx1-Cre;LSL-KrasG12D mice (16). Thus, ICMT deficiency phenocopied Notch1 deficiency both in the pancreas and epidermis of Pdx1-Cre;LSL-KrasG12D mice. This observation suggests that ICMT and Notch1 function in the same pathway, which could be explained by a requirement of carboxyl methylation of an ICMT substrate for efficient Notch1 signaling.

ICMT is required for Notch signaling.

To test the hypothesis that ICMT is required for efficient Notch1 signaling, we used a coculture system that allows for stimulation of Notch1 in euploid U2OS human osteosarcoma cells with a relevant cell-surface ligand and quantification of Notch signaling with a luciferase reporter. We found that silencing ICMT with siRNA significantly decreased Notch1 signaling in response to fibroblasts expressing Jagged-2 (Figure (Figure8A).8A). Similar results were obtained when the same cells were stimulated with fibroblasts expressing Delta-1 (not shown).

Figure 8
ICMT deficiency inhibits Notch1 signaling.

To further test the hypothesis, we used D. melanogaster, a model genetic organism that is well-characterized with respect to the Notch pathway. We drove the expression of an shRNA targeting Drosophila ICMT, known as Ste14, in a tissue-specific fashion using the GAL4/UAS system. UAS-shSte4 expressed in the developing wing using Ap-GAL4 (Figure (Figure8B)8B) or MS1096-GAL4 (Supplemental Figure 6) resulted in adult wings with vein defects identical to those seen in flies with Delta (Dl) loss-of-function alleles (40). Thus, ICMT deficiency in the developing wing phenocopies deficiency of a Notch ligand. Silencing of Icmt in the developing eye using GMR-GAL4 (Figure (Figure8C)8C) gave a rough eye phenotype not specific for, but consistent with, that observed in Dl-mutant flies (40). To confirm the requirement of STE14 for Notch signaling in flies, we studied the expression of the Notch-dependent gene Cut (41) in the developing wing. We induced clones of cells expressing UAS-shSte14 that are marked by UAS-GFP by inducing stochastic expression of GAL4 with heat shock of early larvae. We examined the wing imaginal discs of third instar larvae for expression of CUT by immunofluorescence staining. CUT is normally expressed in a strip 3–4 cells wide at the dorsal-ventral boundary of the disc. Where the GFP-positive clone intersected the line of CUT staining, there was a marked decrease in the number of CUT-positive cells (Figure (Figure8D8D and Supplemental Figure 7). Thus, as was observed in cultured human tumor cells, ICMT is required for efficient Notch signaling in Drosophila.

To further test the idea that inhibition of Notch signaling accounts for the effects of ICMT deficiency in the pancreas, we used compound E, a γ-secretase inhibitor that blocks Notch signaling (Figure (Figure8A).8A). We found that p16INK4A expression in wild-type PDECs shifted from 3D to 2D culture was inhibited by a γ-secretase inhibitor (Supplemental Figure 8). Thus, Notch inhibition in these cells phenocopied ICMT deficiency with regard to p16INK4A expression. Because p16INK4A expression is associated with cell-cycle arrest, this observation is consistent with the mediation of senescence by ICMT-dependent Notch signaling and could explain the tumor-suppressor–like activity of ICMT in the Pdx1-Cre;LSL-KrasG12D model of pancreatic neoplasia.

Among the ways in which Notch1 acts as a tumor suppressor in skin is through the negative regulation of Wnt/β-catenin signaling, such that Wnt signaling is significantly upregulated in Notch1-deficient cells (38, 42). Interestingly, Wnt signaling is also markedly upregulated in the pancreas of Notch1flx/flx;Pdx1-Cre;LSL-KrasG12D mice (16). Staining for β-catenin in the PanIN lesions of Icmtflx/+;Pdx1-Cre;LSL-KrasG12D versus Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice revealed more β-catenin in the ductal epithelial cells of the latter genotype as well as a more cytoplasmic staining pattern characteristic of activated β-catenin (Supplemental Figure 9). Thus, Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice also phenocopied Notch1flx/flx;Pdx1-Cre;LSL-KrasG12D mice with respect to derepression of Wnt signaling.

Discussion

Enzymes that posttranslationally modify the CaaX motif of RAS have long been considered targets for anti-RAS drug discovery (43). The lack of success of FTIs as anticancer drugs does not invalidate this approach because FTIs failed due to alternative prenylation of RAS (8) rather than prenylation-independent RAS oncogenicity. Thus, strategies that effectively curtail CaaX processing are still considered among the most viable approaches to anti-RAS therapeutics. Accordingly, ICMT is considered a good drug target, and enthusiasm for this approach has been bolstered by several preclinical studies that have found a requirement for ICMT in KRAS-mediated cellular transformation (9) and oncogenesis in vivo (10) as well as in studies suggesting that pharmacologic inhibition of ICMT blocks RAS-dependent transformation (44, 45). We set out to solidify this view by studying the role of ICMT in a mouse model of PDA that more faithfully recapitulates human pathology than the cancer models previously examined. To our great surprise, we discovered that ICMT deficiency accelerates the development of both PanINs and PDA in the Pdx1-Cre;LSL-KrasG12D model.

In explaining the consequences of ICMT deficiency, one must consider that RAS is not the only substrate of the enzyme. Indeed, there are on the order of 300 CaaX proteins and another 19 RAB proteins terminating in a CXC sequence that are putative substrates of ICMT (1719). Many of the CaaX substrates are signaling molecules, and RAB proteins are required for vectorial vesicular transport and biogenesis of membrane-bound organelles (46). Our observation that all pancreatic structures develop normally in animals in which ICMT is deleted in pancreatic progenitor cells at E8.5 is therefore somewhat surprising and suggests that, despite the conservation of ICMT throughout eukaryotic evolution, a large subset of ICMT substrates retain biological activity in the absence of carboxyl methylation. Pancreatic development in the absence of ICMT is concordant with the development of many other tissues, including a beating heart, in Icmt-null embryos, which die in utero at E10.5 (47, 48).

There are several possible causes for the acceleration of the neoplastic lesions in Pdx1-Cre;LSL-KrasG12D mice as a consequence of ICMT deficiency. One possibility is that, in the pancreas, unmethylated oncogenic KRAS could be hyperactive as a consequence of altered subcellular distribution. Indeed, we have shown that RAS proteins are able to signal from endomembranes (49). However, ICMT deficiency causes an increase in cytosolic KRAS rather than mislocalization to endomembranes (29, 50), and cytosolic RAS is unable to signal (5). On the contrary, cytosolic, oncogenic RAS has been shown to have a dominant-negative effect on the MAPK pathway (51). The most compelling evidence against unmethylated KRAS gaining function derives from our cell-based studies, which showed that KRAS is unable to transform rodent fibroblasts without ICMT (9) and that there is an ameliorating effect of ICMT deficiency on KRAS-driven myeloproliferative disease and lung tumors in mice (10).

Another possibility is that the acceleration of PanINs in the absence of ICMT might be due to an enhanced stromal reaction. PDA is characterized by an intense desmoplastic reaction that includes inflammation and fibrosis (26). Moreover, pancreatitis is a well-established risk factor for pancreatic cancer (32). Importantly, cerulein-induced acute pancreatitis is associated with ADM and markedly accelerates KRASG12D-induced PanIN progression in a manner very similar to that of ICMT deficiency (52). We observed an exacerbation of both inflammatory cell infiltrates and fibrosis in ICMT-deficient pancreata expressing KRASG12D. Thus, it is possible that ICMT-deficient acinar and/or ductal cells either support intensified inflammation or are slower to resolve inflammation and that this is the trigger for accelerated PanINs in Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice. However, we observed no evidence of increased inflammation in ICMT-deficient pancreata in the absence of oncogenic Kras, even when the mice were allowed to age for a year or more. Moreover, we observed no effect of ICMT deficiency either on the severity of inflammation or on the rate at which the inflammation resolved in cerulein-induced acute or chronic pancreatitis. Although these observations do not rule out an effect of ICMT deficiency on the stromal reaction of PanINs in Pdx1-Cre;LSL-KrasG12D mice, they argue against ICMT deficiency promoting pancreatic inflammation.

A third possibility is that the acceleration of pancreatic neoplasia in Icmtflx/flx;Pdx1-Cre;LSL-KrasG12D mice could be a consequence of effects on ICMT substrates other than KRAS. That is, among the many substrates of ICMT that are signaling molecules, one or more may function as a tumor suppressor in the pancreas and may require carboxyl methylation for biological activity. In this model, ICMT could be considered a tumor suppressor, but one that works indirectly by methylating molecules that are themselves tumor suppressors. Differential expression of substrates might explain why ICMT could have tumor suppressor–like function in one tissue (e.g., pancreas) and not another (e.g., bone marrow). Like many tumor suppressors, loss of function of the relevant ICMT substrate would not be sufficient to provoke neoplasia but, when combined with the activation of an oncogene such as KrasG12D, tumors would be initiated or accelerated. This would explain why no PanINs were observed in the pancreata of Icmtflx/flx;Pdx1-Cre mice. The fact that a dominant-negative mutation of p53 did not accelerate PDA to a significant degree when combined with ICMT deficiency in the Pdx1-Cre;LSL-KrasG12D model does not argue against the tumor suppressor–like activity of ICMT, since the inactivation of p16INK4A also did not accelerate the tumors seen in this model when combined with p53 inactivation (53). Our observation that ICMT-deficient PDECs have a slight growth advantage over wild-type PDECs, even in the absence of oncogenic Ras, and that like KRAS-transformed PDECs, are protected from premature senescence, provides compelling evidence for a cell-autonomous effect of ICMT deficiency in PDECs and is consistent with the notion of a tumor suppressor–like activity of ICMT. The suppression of p16INK4A expression in ICMT-deficient cells is also consistent with a requirement for ICMT in pathways that control the cell cycle, a hallmark of tumor suppressors (54).

There is ample precedence for signaling molecules that can behave as either oncogenes or tumor suppressors, depending on the cellular context. Notch proteins are examples of such molecules. NOTCH1 is a well-established oncogene in T cell acute lymphoblastic leukemia, but acts as a tumor suppressor in skin (42). The complexity of the opposing effects of Notch1 in different tissues also extends to different Notch isoforms in the same tissue: whereas Notch2 is required for PanIN progression in Pdx1-Cre;LSL-KrasG12D mice, Notch1 is not (55), and in fact, the latter isoform behaves like a tumor suppressor in this model (15). The similarities between the effects of Notch1 and ICMT deficiency in the Pdx1-Cre;LSL-KrasG12D mouse model were striking and included not only accelerated PanINs but also papillomas below the pinna on the faces of these animals. This observation strongly suggested that ICMT and Notch1 deficiency affect a common pathway, and the simplest explanation is to hypothesize that Notch1 signaling requires ICMT activity. We confirmed this hypothesis both cell biologically in human osteosarcoma cells and genetically in Drosophila wing development. As currently understood, there is no obvious ICMT substrate in the Notch1 signaling pathway, although it is unlikely that the full details of Notch signaling have been elucidated (42). There is some evidence that endocytosis is required for Notch signaling (56). If so, one could argue that endocytosis requires small GTPases of the RAB and RHO families that are substrates of ICMT. Because of the large number of candidates, the identification of ICMT substrates that play a role in Notch signaling will require extensive investigation but will likely reveal important new features of this highly conserved pathway.

Although at first glance, targeting the three enzymes that modify CaaX sequences, including ICMT, appears to be a straightforward approach to inhibit RAS function, our results reveal a complexity that obfuscates rational drug design. The complexity likely arises from the large repertoire of signaling molecules that are modified by the CaaX processing enzymes. We believe that our results implicate for the first time the Notch pathway as one that must be considered when attempting to predict the pleiotropic effects of ICMT inhibition. Given the fact that in some models, ICMT deficiency ameliorates tumors (10) and that ICMT inhibitors have been shown to have antitumor activity (44, 45), does our surprising observation that ICMT deficiency exacerbates KRAS-driven PanINs in one mouse model mean that ICMT inhibitors cannot be developed as drugs? This will depend on how generalized the results are that we report here.

Methods

Mouse breeding.

Mice with a conditional Icmt allele (Icmtflx) (9) were bred with mice harboring a latent Cre-inducible oncogenic LSL-KrasG12D allele from the endogenous promoter (57) to generate Icmtflx/flx;LSL-KrasG12D mice. These mice were then bred with mice containing a Pdx1-Cre transgene (11) (MMHCC; National Cancer Institute [NCI], Frederick, Maryland, USA) that induces the expression of Cre recombinase in pancreatic progenitor cells. These crosses generated experimental Icmtflx/flx;LSL-KrasG12D;Pdx1-Cre mice and control Icmtflx/+;LSL-KrasG12D;Pdx1-Cre mice that retained a wild-type copy of Icmt. In a separate cross, mice containing Icmtflx, LSL-KrasG12D, and Pdx1-Cre alleles were bred with mice containing a Cre-inducible dominant-negative LSL-p53R172H allele (58) (MMHCC; NCI) to generate experimental Icmtflx/flx;LSL-KrasG12D;Pdx1-Cre;LSL-p53R172H and control Icmtflx/flx;LSL-KrasG12D;Pdx1-Cre;LSL-p53R172H mice. In a third cross, mice containing a Rosa26-LSL-LacZ reporter allele (21) (JAX mice) were bred with Icmtflx/flx;Pdx1-Cre mice. The gene nomenclature used for the different groups of mice refers to the genotype detected in tail DNA at weaning. All mice were maintained on a 129/Sv and C57BL/6 mixed genetic background. Intraperitoneal glucose tolerance tests in mice were carried out as described (59). All animal care and procedures followed NIH guidelines and were approved by the IACUC of New York University School of Medicine.

Genotyping.

Genotyping was performed by PCR amplification of genomic DNA extracted from mouse tails, tumors, tissues and cultured cells. The Icmtflx allele was detected with forward primer 5′-GGGCGGGACGGACAG-3′ and reverse primer 5′-ATGCGCATCTGCCTAAGCTG-3′, which yielded a 600-bp fragment from the Icmtflx allele and a 538-bp fragment from the Icmt+ allele. The Icmt+ allele was detected with forward primer 5′-CCGCTCGCTCCGAATCCAG-3′ and reverse primer 5′-CTCGTAAACCGACCACCAAT-3′, which yielded a 600-bp fragment. The stop cassette in the LSL-KrasG12D allele was detected with forward primer 5′-CCTTTACAAGCGCACGCAGACTGTAGA-3′ and reverse primer 5′-AGCTAGCCACCATGGCTTGAGTAAGTCTGCA-3′, yielding a 600-bp amplified fragment. The activated KrasG12D allele was detected with forward primer 5′-GGGTAGGTGTTGGGATAGCTG-3′ and reverse primer 5′-TCCGAATTCAGTGACTACAGATGTACAGAG-3′, yielding a 320-bp fragment from the activated KrasG12D allele and a 280-bp fragment from the wild-type Kras allele. The LSL-p53R172H allele and wild-type p53 allele were detected with primers 5′-AGCTAG CCACCATGGCTTGAGTAAGTCTGCA-3′, 5′-CTTGGAGACATAGCCACACTG-3′, and 5′-TTACACATCCAGCCTCTGTGG-3′, which generated a 270-bp product for the LSL-p53R172H allele and a 166-bp product for the wild-type allele. The Pdx1-Cre transgene was detected with forward primer 5′-CTGGACTACATCTTGAGTTGC-3′ and reverse primer 5′-GGTGTACGGTCAGTAAATTTG-3′, yielding a 650-bp amplified product. The Rosa26-LSL-LacZ allele and corresponding wild-type allele were detected with primers 5′-GCGAAGAGTTTGTCCTCAACC-3′, 5′-AAAGTCGCTCTGAGTTGTTAT-3′, and 5′-GGAGCGGGAGAAATGGATATG-3′, which generated a 340-bp product for the Rosa26-LSL-LacZ allele and a 650-bp product for the wild-type allele.

In vivo experiments.

The LSL-KrasG12D;Pdx1-Cre and LSL-KrasG12D;Pdx1-Cre;LSL-p53R172H mouse models of pancreatic cancer have been described previously (11, 24). To measure PanIN progression over time, all pancreatic ducts were scored as normal, PanIN-1A, PanIN-1B, PanIN-2, or PanIN-3 in representative H&E-stained sections from mice of varying ages according to established criteria (23). Only the highest-grade lesion in each pancreatic lobule was evaluated. Sections were also examined for evidence of PDA according to established criteria (60). To induce acute or chronic pancreatitis, mice were given 7 hourly i.p. injections of 50 μg/kg cerulein (Sigma-Aldrich) for either 2 days (acute) or thrice weekly for 3 weeks (chronic). Mice were sacrificed either 5 hours or 3 to 7 days after the final injection.

PDEC isolation and culture.

PDECs were isolated from 2- to 3-month-old mice of the genotypes Icmtflx/+, Icmtflx/flx, Icmtflx/+;LSL-KrasG12D, and Icmtflx/+;LSL-KrasG12D and cultured and embedded in 3D Matrigel (BD), as described previously (36). Cells were infected with adenovirus expressing Cre (Ad5CMVCre; University of Iowa, Gene Transfer Vector Core, Iowa City, Iowa, USA) to induce recombination of the floxed alleles as described (37). For all experiments, the PDECs were transferred to 1% Matrigel-coated tissue 2D culture plates and allowed to proliferate. To measure the proliferation rate of PDECs, the cells were trypsinized after 3 days in 2D culture, and 5,000 cells were transferred to 96-well plates. Cell numbers were measured with an MTS assay (Promega). After 12 days in 2D culture, cells were stained for the expression of senescence-associated β-gal as described (37) and counterstained with 1 μg/ml Hoechst 33342 (Invitrogen). Differential interference contrast (DIC) and fluorescent images of cells were taken with a Zeiss Axiovert 200 microscope using a ×20 objective. The area of blue staining per field was measured using MetaMorph software (Molecular Devices) and normalized to the number of nuclei in each field.

Pancreas fractionation.

Pancreatic tissue was homogenized by Dounce in hypotonic buffer (10 mM HEPES, pH 7.3, 100 mM KCl, 3 mM NaCl, 35 mM MgCl2). Membrane (P100) and cytosolic fractions (S100) were isolated from postnuclear supernatants by ultracentrifugation at 100,000 g for 30 minutes. An in vitro assay for ICMT activity was carried out as described (22) using 10 μg of pancreas membrane protein. P100 and S100 fractions (100 μg) were also loaded onto SDS-PAGE gels for subsequent immunoblot analysis.

Immunoblot.

Cells were lysed in Tris-Glycine SDS Sample Buffer (Invitrogen), and the lysates were separated by electrophoresis in SDS polyacrylamide gels, then transferred to nitrocellulose membranes. After blocking, the membranes were incubated with the following primary antibodies: rabbit anti-KRAS, rabbit anti-p16INK4A, rabbit anti-ERK1, goat anti–Na+K+-ATPase, rabbit anti-RhoGDI, goat anti–β-1,4-gal-T4 (all from Santa Cruz Biotechnology Inc.), mouse anti–β-tubulin (E7, developed by M. Klymkowsky and obtained from Developmental Studies Hybridoma Bank), rabbit anti-Notch1 (Cell Signaling Technology), and mouse anti-RAS (RAS10; Calbiochem). Secondary antibodies were IRDye 800–conjugated goat anti-rabbit or IRDye 680–conjugated goat anti-mouse (Li-COR). Blots were visualized with the Odyssey Infrared Imaging System (Li-COR) and quantified using Odyssey software.

GST-RBD pulldown for active RAS.

HeLa cells were serum starved in 0.5% serum overnight before stimulation with 10 ng/ml EGF for 3 minutes. Cells were lysed in magnesium lysis buffer (25 mM HEPES, pH 7.5, 125 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 1% IGEPAL CA-630, and 10% glycerol). GST-RBD pulldown of active GTP-bound RAS was carried out as described (61, 62). The lysed cellular material (1%) was saved prior to pulldown as a loading control for the total amount of RAS present.

Histology.

Mouse tissues were fixed in 10% formalin overnight. After fixation, tissues were dehydrated in 50% to 100% ethanol, cleared in xylene, and embedded in paraffin. Sections (5-μm) were stained with either H&E or Masson’s trichrome and visualized by light microscopy using a Zeiss Axiovert 200 microscope. Immunohistochemistry on paraffin sections was performed as described (37) using the following antibodies: mouse anti–β-catenin (BD), rabbit anti-pERK, anti–α-smooth muscle actin (Novus Biologicals), and anti-Ki67 (Cell Signaling Technology). For immunofluorescence, samples of pancreas were embedded in OCT compound (Tissue-Tek) and snap-frozen. Sections (8-μm) were fixed in 4% paraformaldehyde for 10 minutes, permeabilized in 0.2% Triton X-100 for 20 minutes, and blocked with 1% IgG-free BSA and 50 μg/ml donkey IgG (Jackson ImmunoResearch) for 1 hour. The sections were incubated with primary antibodies diluted in 1% BSA and 0.1% Tween-20 overnight at 4°C, and the Alexa Fluor–labeled secondary antibodies (Invitrogen) were diluted in 1% BSA for 1 hour. The sections were washed in PBS containing 1 μg/ml Hoechst 33342 (Invitrogen) and mounted with fluorescent mounting media (DakoCytomation). Drosophila wing discs were fixed and processed in the same way before mounting with Vectashield (Vector Laboratories). Tissues were visualized by fluorescence microscopy using a Zeiss Axiovert 200 microscope or a Zeiss LSM 510 confocal microscope. The following antibodies were used: rat anti-CD45 (BD); rat anti-CK19 (Troma-III, developed by Rolf Kemler and obtained from Developmental Studies Hybridoma Bank); goat anti-amylase (Santa Cruz Biotechnology Inc.); and mouse anti-CUT (2B10, developed by Rubin, G.M. and obtained from Developmental Studies Hybridoma Bank). Staining for β-gal expression was carried out on 8-μm frozen sections of pancreatic tissue. Sections were fixed in 2% formaldehyde/0.2% glutaraldehyde in PBS for 5 minutes, washed in PBS, and stained at 37°C for 12 to 16 hours in X-gal solution (1 mg/ml X-Gal, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, and 1 mM MgCl2 in PBS). Slides were counterstained with eosin, mounted with Permount (Fisher), and imaged with a wide-field fluorescence microscope.

Luciferase assays.

Luciferase assays for Notch1 activity were carried out as described (63). All assays were performed in 96-well plates, and luciferase expression was measured using a Dual-Glo Luciferase kit (Promega) and detected in a plate reader. Icmt knockdown was performed with an siRNA SMARTpool (Dharmacon). A nontargeting siRNA pool was used as a negative control. Knockdown of ICMT was validated in each cell line tested by immunoblot using an ICMT antibody (Proteintech). Compound E (CE) was obtained from Enzo Lifesciences.

Drosophila stocks and genetics.

The UAS-ShSte14 stock was obtained from The Bloomington Drosophila Stock Center (stock number 34996). Ap-GAL4, MS1096-GAL4, and GMR-GAL4 lines were obtained from Ramanuj DasGupta (NYU School of Medicine). UAS-shSte14 males were crossed with virgin females from the GAL4 driver lines at 29°C. For heat-shock experiments, yw; Act>y+>Gal4, UAS-GFP males were crossed with ywhsflp122; UAS-ShSte14 virgins at 25°C. Larvae were heat shocked at 37°C for 10 minutes approximately 30 hours after egg-laying. Wing imaginal discs were dissected from third instar larvae.

Statistics.

PanIN frequencies were compared by means of a generalized linear model for binomial data using age and genotype as covariates. All analyses were carried out using R (64). All other statistical analyses were carried out using a Student’s t test. P values of less than 0.05 were considered significant.

Supplementary Material

Supplemental data:

Acknowledgments

We thank Stephen Blacklow for providing expert advice as well as cell lines and reagents for the Notch1 luciferase assay. We thank Jonathan Court for statistical analysis of data. We thank Cynthia Loomis, Luis Chiriboga, and the NYU Langone Medical Center Histopathology and Immunohistochemistry Core Facilities for their assistance with specimen preparation and histology. We thank Jessica Treisman and Ramanuj DasGupta for fly stocks and discussions. We thank Rebecca Zuckerman and Christopher Graffeo for technical assistance. This work was supported by NIH Grants CA118495, CA116034, and GM055279 and by funding from the Jeffrey Rosenzweig Foundation for Pancreatic Cancer Research (to M.R. Philips). Support was also provided by NIH Awards DK085278 and CA155649 (to G. Miller) and 5R01CA55360 and 5R01GM078266 (to D. Bar-Sagi). This work was also supported in part by NCI grant 5P30CA016087-32.

Footnotes

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2013;123(11):4681–4694. doi:10.1172/JCI65764.

References

1. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49(17):4682–4689. [PubMed]
2. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11–22. doi: 10.1038/nrc969. [PubMed] [Cross Ref]
3. Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer. 2010;10(12):842–857. doi: 10.1038/nrc2960. [PMC free article] [PubMed] [Cross Ref]
4. Barbacid M. ras genes. Annu Rev Biochem. 1987;56:779–827. doi: 10.1146/annurev.bi.56.070187.004023. [PubMed] [Cross Ref]
5. Willumsen BM, Christensen A, Hubbert NL, Papageorge AG, Lowy DR. The p21 ras C-terminus is required for transformation and membrane association. Nature. 1984;310(5978):583–586. doi: 10.1038/310583a0. [PubMed] [Cross Ref]
6. Wright LP, Philips MR. Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of Ras. J Lipid Res. 2006;47(5):883–891. doi: 10.1194/jlr.R600004-JLR200. [PubMed] [Cross Ref]
7. Cox AD, Der CJ. Farnesyltransferase inhibitors: promises and realities. Curr Opin Pharmacol. 2002;2(4):388–393. doi: 10.1016/S1471-4892(02)00181-9. [PubMed] [Cross Ref]
8. Whyte DB, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997;272(22):14459–14464. doi: 10.1074/jbc.272.22.14459. [PubMed] [Cross Ref]
9. Bergo MO, et al. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest. 2004;113(4):539–550. doi: 10.1172/JCI18829. [PMC free article] [PubMed] [Cross Ref]
10. Wahlstrom AM, et al. Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. Blood. 2008;112(4):1357–1365. doi: 10.1182/blood-2007-06-094060. [PMC free article] [PubMed] [Cross Ref]
11. Hingorani SR, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4(6):437–450. doi: 10.1016/S1535-6108(03)00309-X. [PubMed] [Cross Ref]
12. Yonezawa S, Higashi M, Yamada N, Goto M. Precursor lesions of pancreatic cancer. Gut Liver. 2008;2(3):137–154. doi: 10.5009/gnl.2008.2.3.137. [PMC free article] [PubMed] [Cross Ref]
13. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53(4):549–554. doi: 10.1016/0092-8674(88)90571-5. [PubMed] [Cross Ref]
14. Shi C, et al. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. Mol Cancer Res. 2009;7(2):230–236. doi: 10.1158/1541-7786.MCR-08-0206. [PMC free article] [PubMed] [Cross Ref]
15. Hanlon L, et al. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res. 2010;70(11):4280–4286. doi: 10.1158/0008-5472.CAN-09-4645. [PMC free article] [PubMed] [Cross Ref]
16. Mazur PK, et al. Identification of epidermal Pdx1 expression discloses different roles of Notch1 and Notch2 in murine Kras(G12D)-induced skin carcinogenesis in vivo. PLoS One. 2010;5(10):e13578. doi: 10.1371/journal.pone.0013578. [PMC free article] [PubMed] [Cross Ref]
17. Maurer-Stroh S, Koranda M, Benetka W, Schneider G, Sirota FL, Eisenhaber F. Towards complete sets of farnesylated and geranylgeranylated proteins. PLoS Comput Biol. 2007;3(4):e66. doi: 10.1371/journal.pcbi.0030066. [PMC free article] [PubMed] [Cross Ref]
18. Ashar HR, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 2000;275(39):30451–30457. doi: 10.1074/jbc.M003469200. [PubMed] [Cross Ref]
19. Reid TS, Terry KL, Casey PJ, Beese LS. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol. 2004;343(2):417–433. doi: 10.1016/j.jmb.2004.08.056. [PubMed] [Cross Ref]
20. Gannon M, Herrera PL, Wright CV. Mosaic Cre-mediated recombination in pancreas using the pdx-1 enhancer/promoter. Genesis. 2000;26(2):143–144. doi: 10.1002/(SICI)1526-968X(200002)26:2<143::AID-GENE13>3.0.CO;2-L. [PubMed] [Cross Ref]
21. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 1999;21(1):70–71. doi: 10.1038/5007. [PubMed] [Cross Ref]
22. Choy E, Philips M. Expression and activity of human prenylcysteine-directed carboxyl methyltransferase. Methods Enzymol. 2000;325:101–114. [PubMed]
23. Hruban RH, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28(8):977–987. doi: 10.1097/01.pas.0000126675.59108.80. [PubMed] [Cross Ref]
24. Hingorani SR, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7(5):469–483. doi: 10.1016/j.ccr.2005.04.023. [PubMed] [Cross Ref]
25. Zhu L, Shi G, Schmidt CM, Hruban RH, Konieczny SF. Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol. 2007;171(1):263–273. doi: 10.2353/ajpath.2007.061176. [PMC free article] [PubMed] [Cross Ref]
26. Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. J Cell Biochem. 2007;101(4):887–907. doi: 10.1002/jcb.21209. [PubMed] [Cross Ref]
27. Bachem MG, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology. 2005;128(4):907–921. doi: 10.1053/j.gastro.2004.12.036. [PubMed] [Cross Ref]
28. Michaelson D, et al. Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol Biol Cell. 2005;16(4):1606–1616. doi: 10.1091/mbc.E04-11-0960. [PMC free article] [PubMed] [Cross Ref]
29. Bergo MO, Leung GK, Ambroziak P, Otto JC, Casey PJ, Young SG. Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells. J Biol Chem. 2000;275(23):17605–17610. doi: 10.1074/jbc.C000079200. [PubMed] [Cross Ref]
30. Ijichi H, et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev. 2006;20(22):3147–3160. doi: 10.1101/gad.1475506. [PMC free article] [PubMed] [Cross Ref]
31. Guerra C, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007;11(3):291–302. doi: 10.1016/j.ccr.2007.01.012. [PubMed] [Cross Ref]
32. Lowenfels AB, Maisonneuve P, Lankisch PG. Chronic pancreatitis and other risk factors for pancreatic cancer. Gastroenterol Clin North Am. 1999. 28 3 673 685 , x. 10.1016/S0889-8553(05)70080-7 [PubMed] [Cross Ref]
33. Lampel M, Kern HF. Acute interstitial pancreatitis in the rat induced by excessive doses of a pancreatic secretagogue. Virchows Arch A Pathol Anat Histol. 1977;373(2):97–117. doi: 10.1007/BF00432156. [PubMed] [Cross Ref]
34. Watanabe O, Baccino FM, Steer ML, Meldolesi J. Supramaximal caerulein stimulation and ultrastructure of rat pancreatic acinar cell: early morphological changes during development of experimental pancreatitis. Am J Physiol. 1984;246(4 pt 1):G457–467. [PubMed]
35. Bedrosian AS, et al. Dendritic cells promote pancreatic viability in mice with acute pancreatitis. Gastroenterology. 2011;141(5):1915–1914. doi: 10.1053/j.gastro.2011.07.033. [PMC free article] [PubMed] [Cross Ref]
36. Agbunag C, Lee KE, Buontempo S, Bar-Sagi D. Pancreatic duct epithelial cell isolation and cultivation in two-dimensional and three-dimensional culture systems. Methods Enzymol. 2006;407:703–710. [PubMed]
37. Lee KE, Bar-Sagi D. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell. 2010;18(5):448–458. doi: 10.1016/j.ccr.2010.10.020. [PMC free article] [PubMed] [Cross Ref]
38. Nicolas M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet. 2003;33(3):416–421. doi: 10.1038/ng1099. [PubMed] [Cross Ref]
39. Demehri S, Turkoz A, Kopan R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell. 2009;16(1):55–66. doi: 10.1016/j.ccr.2009.05.016. [PMC free article] [PubMed] [Cross Ref]
40. Parody TR, Muskavitch MA. The pleiotropic function of Delta during postembryonic development of Drosophila melanogaster. Genetics. 1993;135(2):527–539. [PMC free article] [PubMed]
41. Micchelli CA, Rulifson EJ, Blair SS. The function and regulation of cut expression on the wing margin of Drosophila: Notch, Wingless and a dominant negative role for Delta and Serrate. Development. 1997;124(8):1485–1495. [PubMed]
42. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 2003;3(10):756–767. doi: 10.1038/nrc1186. [PubMed] [Cross Ref]
43. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol. 2012;13(1):39–51. doi: 10.1038/nrm3255. [PMC free article] [PubMed] [Cross Ref]
44. Winter-Vann AM, et al. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci U S A. 2005;102(12):4336–4341. doi: 10.1073/pnas.0408107102. [PMC free article] [PubMed] [Cross Ref]
45. Judd WR, et al. Discovery and SAR of methylated tetrahydropyranyl derivatives as inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT). J Med Chem. 2011;54(14):5031–5047. doi: 10.1021/jm200249a. [PubMed] [Cross Ref]
46. Grosshans BL, Ortiz D, Novick P. Rabs and their effectors: achieving specificity in membrane traffic. Proc Natl Acad Sci U S A. 2006;103(32):11821–11827. doi: 10.1073/pnas.0601617103. [PMC free article] [PubMed] [Cross Ref]
47. Bergo MO, et al. Isoprenylcysteine carboxyl methyltransferase deficiency in mice. J Biol Chem. 2001;276(8):5841–5845. doi: 10.1074/jbc.C000831200. [PubMed] [Cross Ref]
48. Lin X, Jung J, Kang D, Xu B, Zaret KS, Zoghbi H. Prenylcysteine carboxylmethyltransferase is essential for the earliest stages of liver development in mice. Gastroenterology. 2002;123(1):345–351. doi: 10.1053/gast.2002.34279. [PubMed] [Cross Ref]
49. Chiu VK, et al. Ras signalling on the endoplasmic reticulum and the Golgi. Nat Cell Biol. 2002;4(5):343–350. [PubMed]
50. Michaelson D, et al. Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol Biol Cell. 2005;16(4):1606–1616. doi: 10.1091/mbc.E04-11-0960. [PMC free article] [PubMed] [Cross Ref]
51. Fiordalisi JJ, Holly SP, Johnson RL, Parise LV, Cox AD. A distinct class of dominant negative Ras mutants: cytosolic GTP-bound Ras effector domain mutants that inhibit Ras signaling and transformation and enhance cell adhesion. J Biol Chem. 2002;277(13):10813–10823. doi: 10.1074/jbc.M107684200. [PubMed] [Cross Ref]
52. Carriere C, Young AL, Gunn JR, Longnecker DS, Korc M. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem Biophys Res Commun. 2009;382(3):561–565. doi: 10.1016/j.bbrc.2009.03.068. [PMC free article] [PubMed] [Cross Ref]
53. Bardeesy N, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A. 2006;103(15):5947–5952. doi: 10.1073/pnas.0601273103. [PMC free article] [PubMed] [Cross Ref]
54. Sherr CJ. Principles of tumor suppression. Cell. 2004;116(2):235–246. doi: 10.1016/S0092-8674(03)01075-4. [PubMed] [Cross Ref]
55. Mazur PK, et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2010;107(30):13438–13443. doi: 10.1073/pnas.1002423107. [PMC free article] [PubMed] [Cross Ref]
56. Le Borgne R, Bardin A, Schweisguth F. The roles of receptor and ligand endocytosis in regulating Notch signaling. Development. 2005;132(8):1751–1762. doi: 10.1242/dev.01789. [PubMed] [Cross Ref]
57. Jackson EL, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15(24):3243–3248. doi: 10.1101/gad.943001. [PMC free article] [PubMed] [Cross Ref]
58. Olive KP, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119(6):847–860. doi: 10.1016/j.cell.2004.11.004. [PubMed] [Cross Ref]
59. Heikkinen S, Argmann CA, Champy MF, Auwerx J. Evaluation of glucose homeostasis. Curr Protoc Mol Biol. 2007;Chapter 29:Unit 29B.3. [PubMed]
60. Hruban RH, Fukushima N. Pancreatic adenocarcinoma: update on the surgical pathology of carcinomas of ductal origin and PanINs. Mod Pathol. 2007;20(suppl 1):S61–S70. doi: 10.1038/modpathol.3800685. [PubMed] [Cross Ref]
61. Ahearn IM, et al. FKBP12 binds to acylated H-ras and promotes depalmitoylation. Mol Cell. 2011;41(2):173–185. doi: 10.1016/j.molcel.2011.01.001. [PMC free article] [PubMed] [Cross Ref]
62. de Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene. 1997;14(5):623–625. doi: 10.1038/sj.onc.1201005. [PubMed] [Cross Ref]
63. Aste-Amezaga M, et al. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One. 2010;5(2):e9094. doi: 10.1371/journal.pone.0009094. [PMC free article] [PubMed] [Cross Ref]
64. R Development Core Team . R: A Language Environment For Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2012.

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...